Skip to main content
Premium Trial:

Request an Annual Quote

Genomas, Partners Share SBIR Grant for DNA-Guided Therapy Management System

NEW YORK (GenomeWeb News) – Genomas, along with partners from Hartford Hospital, the Rogosin Institute, and the University of California San Francisco, will use a $1.2 million Small Business Innovation Research grant to develop DNA-guided clinical management systems to predict and compare an individual's risk of certain adverse reactions to statin medications, the company said Wednesday.
 
Statins are among the most popularly prescribed drugs in the world, but also have adverse nerve and muscle-related side effects such as aches, cramps, weakness, and injury that disable 10 percent of the patients and require therapeutic changes.
 
The research that led to the award was conducted by Hartford Hospital and UCSF and was published in the September 2007 journal Muscle & Nerve.
 
The Hartford, Conn.-based company will integrate the knowledge of Hartford Hospital with its physiogenomics technology to develop the PhyzioType Clinical Management System, which will include a group of inherited DNA markers genotyped by arrays and interpreted by an algorithm. The system will help doctors predict and compare the risk of side effects for individual patients, the company said.
 
Genomas noted that to date it has received $3.1 million in NIH SBIR funding to develop the PhyzioType.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.